Trial Profile
An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Danicopan (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease
- 09 Aug 2022 Status changed from completed to discontinued.
- 07 Mar 2022 Inclusion criteria has been updated to remove the upper age limit of 65 years.
- 18 Oct 2021 Inclusion criteria has been updated to decrease the lower age limit of subjects from 17 years to 12 years.